Generated by AI
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways of cancer. It maintains a broad pipeline of product candidates, with an initial emphasis on validated oncology targets designed to address large patient populations. The company advances innovative therapies, including a first-in-class WEE1 inhibitor in late-stage development and biomarker-driven treatments for ovarian cancer. Zentalis Pharmaceuticals, Inc. operates within the health technology and biotechnology sectors, contributing to oncology research by pursuing small molecule approaches to improve cancer treatment options. Founded in 2014 and headquartered in San Diego, California, it dedicates efforts to groundbreaking research in clinical-stage oncology programs.
Website10275 Science Center Dr.
San Diego, CA, 92121
United States
The latest articles about ZNTL.
Summary of Jul 17's posts. Generated by AI.
Summary of Jun 30's posts. Generated by AI.
Summary of Apr 10's posts. Generated by AI.
Summary of Jun 30's posts. Generated by AI.
Investors talking about ZNTL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.